(Q33744195)

29 July 2017

title

Clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple myeloma (English)

1 reference

29 July 2017

1 reference

2

Angela Dispenzieri

1 reference

29 July 2017

3

Martha Q Lacy

1 reference

29 July 2017

7

S Vincent Rajkumar

1 reference

29 July 2017

8

Morie A Gertz

1 reference

29 July 2017

5

Suzanne R Hayman

1 reference

29 July 2017

6

Steven R Zeldenrust

1 reference

29 July 2017

4

Francis Buadi

1 reference

29 July 2017

9

Shaji K Kumar

1 reference

29 July 2017

Sumit Madan

1

1 reference

29 July 2017

language of work or name

English

0 references

publication date

1 March 2010

1 reference

29 July 2017

1 reference

29 July 2017

volume

85

1 reference

29 July 2017

issue

3

1 reference

29 July 2017

page(s)

232-238

1 reference

Amyloidosis: 2008 BMT Tandem Meetings (February 13-17, San Diego).

29 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2843113

Multiple myeloma-associated AL amyloidosis: is a distinctive therapeutic approach warranted?

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2843113

Prevalence of monoclonal gammopathy of undetermined significance

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2843113

Clinical aspects of systemic amyloid diseases.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2843113

Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2843113

Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2843113

Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2843113

Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain-associated amyloidosis (AL).

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2843113

Autologous stem cell transplantation for primary systemic amyloidosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2843113

Primary systemic amyloidosis: clinical and laboratory features in 474 cases.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2843113

Diagnostic criteria of multiple myeloma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2843113

Multiple myeloma-associated amyloidosis is an independent high-risk prognostic factor.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2843113

Guidelines on the diagnosis and management of AL amyloidosis

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2843113

A long-term study of prognosis in monoclonal gammopathy of undetermined significance.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2843113

Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2843113

Multicentre versus single centre approach to rare diseases: The model of systemic light chain amyloidosis

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2843113

Incidence and impact of light chain associated (AL) amyloidosis on the prognosis of patients with multiple myeloma treated with autologous transplantation

30 October 2018

1 reference

12 December 2020

Primary systemic amyloidosis with delayed progression to multiple myeloma

1 reference

12 December 2020

The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement

1 reference

12 December 2020

Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients

1 reference

12 December 2020

Severity of Baseline Proteinuria Predicts Renal Response in Immunoglobulin Light Chain-Associated Amyloidosis after Autologous Stem Cell Transplantation

1 reference

12 December 2020

Identifiers

DOI

10.4065/MCP.2009.0547

1 reference

29 July 2017

1 reference

29 July 2017

1 reference